CoChat
Sign Up
Cited by 24

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia

Fu, Lin, Shi, Jinlong, Liu, Anqi, Zhou, Lei, Jiang, Mengmeng, Fu, Huaping, Xu, Keman, Li, Dandan, Deng, Ailing, Zhang, Qingyi, Pang, Yifan, Guo, Yujie, Hu, Kai, Zhou, Jiansuo, Wang, Yapeng, Huang, Wenrong, Jing, Yu, Dou, Liping, Wang, Lili, Xu, Kailin, Ke, Xiaoyan, Nervi, Clara, Li, Yonghui, Yu, Li·2017·International Journal of Cancer
DOI 10.1002/ijc.30481
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.30481

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 34

  1. Wang, 1997, Transformation properties of the ETO gene, fusion partner in t(8:21) leukemias, Cancer Res, 57, 2951
  2. Fu, 2016, High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia, Oncotarget, 29, 15828, 10.18632/oncotarget.7489 · DOI
  3. Ben-Ami, 2013, Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1, Cell Rep, 4, 1131, 10.1016/j.celrep.2013.08.020 · DOI
  4. Goyama, 2014, Posttranslational modifications of RUNX1 as potential anticancer targets, Oncogene, 34, 3483, 10.1038/onc.2014.305 · DOI
  5. Goyama, 2013, Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells, J Clin Invest, 123, 3876, 10.1172/JCI68557 · DOI
  6. Migas, 2014, RUNX1T1/MTG8/ETO gene expression status in human t(8;21)(q22;q22)-positive acute myeloid leukemia cells, Leukemia Res, 38, 1102, 10.1016/j.leukres.2014.06.002 · DOI
  7. Gardini, 2008, AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets, PLoS Genet, 4, e1000275, 10.1371/journal.pgen.1000275 · DOI
  8. Steffen, 2011, AML1/ETO induces self-renewal in hematopoietic progenitor cells via the Groucho-related amino-terminal AES protein, Blood, 117, 4328, 10.1182/blood-2009-09-242545 · DOI
  9. Wang, 2011, C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice, Proc Natl Acad Sci USA, 108, 2450, 10.1073/pnas.1019625108 · DOI
  10. Huang, 2012, CD99 triggers upregulation of miR-9-modulated PRDM1/BLIMP1 in Hodgkin/Reed-Sternberg cells and induces redifferentiation, Int J Cancer, 131, E382, 10.1002/ijc.26503 · DOI
  11. Tsai, 2011, Aberrant hypermethylation of miR-9 genes in gastric cancer, Epigenetics, 6, 1189, 10.4161/epi.6.10.16535 · DOI
  12. Chen, 2013, miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia, Proc Natl Acad Sci USA, 110, 11511, 10.1073/pnas.1310144110 · DOI
  13. Senyuk, 2013, Critical role of miR-9 in myelopoiesis and EVI1-induced leukemogenesis, Proc Natl Acad Sci USA, 110, 5594, 10.1073/pnas.1302645110 · DOI
  14. Wang, 2013, Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia-implications on constitutive activation of NFkappaB pathway, Mol Cancer, 12, 173, 10.1186/1476-4598-12-173 · DOI
  15. Emmrich, 2014, miR-9 is a tumor suppressor in pediatric AML with t(8;21), Leukemia, 28, 1022, 10.1038/leu.2013.357 · DOI
  16. Jongen-Lavrencic, 2008, MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia, Blood, 111, 5078, 10.1182/blood-2008-01-133355 · DOI
  17. Li, 2008, Distinct microRNA expression profiles in acute myeloid leukemia with common translocations, Proc Natl Acad Sci USA, 105, 15535, 10.1073/pnas.0808266105 · DOI
  18. Sun, 2013, A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis, Nature, 500, 93, 10.1038/nature12287 · DOI
  19. Heidenreich, 2003, AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells, Blood, 101, 3157, 10.1182/blood-2002-05-1589 · DOI
  20. Li, 2013, Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway, Blood, 121, 499, 10.1182/blood-2012-07-444729 · DOI
  21. Liu, 2008, miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes, Nucleic Acids Res, 36, 5391, 10.1093/nar/gkn522 · DOI
  22. Fu, 2014, AML1-ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia, FEBS J, 281, 1123, 10.1111/febs.12673 · DOI
  23. 2013, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia, N Engl J Med, 368, 2059, 10.1056/NEJMoa1301689 · DOI · Paper page
  24. Liu, 2007, Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity, Cancer Cell, 11, 483, 10.1016/j.ccr.2007.04.010 · DOI
  25. Peterson, 2004, The 8;21 translocation in leukemogenesis, Oncogene, 23, 4255, 10.1038/sj.onc.1207727 · DOI
  26. Zhang, 2012, MicroRNAs in erythroid and megakaryocytic differentiation and megakaryocyte-erythroid progenitor lineage commitment, Leukemia, 26, 2310, 10.1038/leu.2012.137 · DOI
  27. Bartel, 2004, Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs, Nat Rev Genet, 5, 396, 10.1038/nrg1328 · DOI
  28. Fazi, 2007, Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein, Cancer Cell, 12, 457, 10.1016/j.ccr.2007.09.020 · DOI
  29. Bots, 2014, Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors, Blood, 123, 1341, 10.1182/blood-2013-03-488114 · DOI
  30. Harada, 2004, High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia, Blood, 103, 2316, 10.1182/blood-2003-09-3074 · DOI · Paper page
  31. Kohlmann, 2010, Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1, J Clin Oncol, 28, 3858, 10.1200/JCO.2009.27.1361 · DOI
  32. Tang, 2009, AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations, Blood, 114, 5352, 10.1182/blood-2009-05-223784 · DOI
  33. Schnittger, 2011, RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis, Blood, 117, 2348, 10.1182/blood-2009-11-255976 · DOI
  34. Guo, 2009, MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1, FEBS J, 276, 5537, 10.1111/j.1742-4658.2009.07237.x · DOI

Cited by

See all 24

Metadata

Authors
Fu, L., Shi, J., Liu, A., Zhou, L., Jiang, M., Fu, H., Xu, K., Li, D., Deng, A., Zhang, Q., Pang, Y., Guo, Y., Hu, K., Zhou, J., Wang, Y., Huang, W., Jing, Y., Dou, L., Wang, L., Xu, K., Ke, X., Nervi, C., Li, Y., & Yu, L.
Affiliations
  • Department of Hematology and Lymphoma Research Center; Peking University, Third Hospital; Beijing 100191 China
  • Department of Biomedical Engineering; Chinese PLA General Hospital; Beijing 100853 China
  • Department of Hematology; Chinese PLA General Hospital; Beijing 100853 China
  • Department of nuclear medicine; Chinese PLA General Hospital; Beijing 100853 China
  • College of medical laboratory science and technology; Harbin Medical University; Daqing 163319 China
  • Department of Medicine; William Beaumont Hospital; Royal Oak MI 48073
  • College of Science; North China University of Technology; Beijing 100144 China
  • Department of clinical laboratory; Peking University, Third Hospital; Beijing 100191 China
  • Department of reproduction center; Peking University, Third Hospital; Beijing 100191 China
  • Department of Hematology; The Affiliated Hospital of Xuzhou Medical University; Xuzhou 221002 China
  • Department of Medico-Surgical Sciences and Biotechnologies; University of Rome “La Sapienza” Polo Pontino; Latina 04100 Italy
Venue
International Journal of Cancer
Publisher
Wiley
Published
2016-11-10
Volume
140
Issue
3
Pages
653-661
ISSN
0020-7136
DOI
10.1002/ijc.30481
Cited by
24
References
1
Language
en
Licence
Funders
  • National Natural Science Foundation of China (81500118, 61501519, 81370635, 81270611, 81470010)
  • Chinese PLA General Hospital Nursery Foundation (14KMM38)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review